Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

396 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving docetaxel after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving docetaxel after surgery is more effective than observation in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying docetaxel to see how well it works compared with observation in treating patients who have undergone radical prostatectomy for prostate cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Compare time to prostate-specific antigen (PSA) progression in patients with margin-positive tumors after undergoing radical prostatectomy for high-grade prostate cancer treated with docetaxel versus observation.

Secondary

* Compare PSA doubling time in patients treated with these regimens.
* Compare quality of life of these patients.
* Compare overall and metastasis-free survival of patients treated with these regimens.

OUTLINE: This is a prospective, open-label, randomized, multicenter study. Patients are stratified according to participating center and tumor stage (pT2 vs pT3). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, directly after and 6 months after completing study treatment, and then annually thereafter.

* Arm II: Patients undergo observation until PSA progression (defined as PSA ≥ 0.5 ng/mL) Quality of life is assessed at baseline, week 19, and annually thereafter.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 396 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stage IIB prostate cancer stage IIA prostate cancer stage III prostate cancer adenocarcinoma of the prostate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

docetaxel

Intervention Type DRUG

active surveillance

Intervention Type OTHER

adjuvant therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma of the prostate meeting one of the following criteria after undergoing radical prostatectomy:

* pT2 with Gleason score 4+3 or 8-10 and positive margins in the radical prostatectomy specimen
* Any pT3a tumor with Gleason score ≥ 4+3
* pT3b tumor with Gleason score ≥ 7
* Negative lymph nodes at histological examination (N0)
* Patients with a preoperative prostate-specific antigen (PSA) ≥ 10.0 ng/mL should have undergone a lymph node dissection
* Postoperative PSA must be \< 0.5 ng/mL
* Considered at high risk for recurrent disease
* No metastatic (M0) disease

* Negative bone scan

PATIENT CHARACTERISTICS:

* WHO/ECOG performance status 0-1
* Hemoglobin ≥ 11.0 g/dL
* Neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 150,000/mm³
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Bilirubin normal
* AST and ALT ≤ 1.5 times ULN
* Alkaline phosphatase \< 1.5 times ULN
* No active untreated infectious disease (e.g., tuberculosis or methicillin-resistant Staphylococcus aureus)
* No active gastric ulcer
* No known hypersensitivity to polysorbate 80
* No symptomatic peripheral neuropathy ≥ grade 2
* No myocardial infarction within the past 6 months
* No other unstable cardiovascular disease within the past 6 months
* No other serious illness or medical condition
* No altered psychological or physical state that would preclude study compliance
* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior hormonal therapy (e.g., luteinizing hormone-releasing hormone analogues and/or antiandrogens) affecting prostate cancer cells
* No prior radiotherapy to the pelvis
* No prior chemotherapy
* More than 6 months since prior systemic corticosteroids
* No other concurrent anticancer therapy or investigational drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Goran Ahlgren, MD, PhD

Role: STUDY_CHAIR

Skane University Hospital

Per Flodgren, MD, PhD

Role:

Lund University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus Universitetshospital - Aarhus Sygehus

Aarhus, , Denmark

Site Status RECRUITING

Copenhagen County Herlev University Hospital

Copenhagen, , Denmark

Site Status RECRUITING

Tampere University Hospital

Tampere, , Finland

Site Status RECRUITING

Landspitalinn University Hospital

Reykjavik, , Iceland

Site Status RECRUITING

Ullevaal University Hospital

Oslo, , Norway

Site Status RECRUITING

Norwegian University of Science and Technology

Trondheim, , Norway

Site Status RECRUITING

Lund University Hospital

Lund, , Sweden

Site Status RECRUITING

Malmo University Hospital

Malmo, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark Finland Iceland Norway Sweden

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Borre, MD, PhD, DMsci

Role: primary

Lisa Sengelov, MD, PhD

Role: primary

Pirkko Kellokumpu-Lehtinen

Role: primary

Asgerdur Sverrisdottir, MD

Role: primary

Jon R. Iversen, MD

Role: primary

Anders Angelsen, MD, PhD

Role: primary

Per Flodgren, MD, PhD

Role: primary

Goran Ahlgren, MD, PhD

Role: primary